Similarly, AZD6738, an orally administered and highly potent ATR inhibitor, is being evaluated in a Phase I clinical trial in combination with paclitaxel for patients with advanced solid tumours and non-small cell lung cancer (NSCLC). The gene discussed is ATR; the disease is non-small cell lung carcinoma.